Octreotide
Main evidence: Human clinical trials. Updated 2026-10-28.
What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.
Summary
Octreotide is an Australian-registered prescription somatostatin analogue used for specific hormone-related disorders and selected neuroendocrine tumours. Human trials support disease-specific symptom, biochemical, or tumour-progression outcomes; they do not establish wellness, bodybuilding, or generic anti-ageing benefits. Immediate-release and depot products have different routes and protocols.
What the sources say
- The Australian Sandostatin LAR product information lists use for acromegaly, symptom relief in selected functional gastro-entero-pancreatic tumours, and progressive well-differentiated advanced midgut or suspected-midgut neuroendocrine tumours. The anti-tumour indication is specific and should not be generalized to all cancers. (Manufacturer information; Therapeutic Goods Administration, AusPAR: Octreotide; Australian Sandostatin LAR Product Information approved with AusPAR, final 2012-02-14, 2012-02-14)
- The TGA ARTG identifies Sandostatin LAR as a registered modified-release octreotide injection with active licence status. Its registration does not establish use for unlisted wellness or performance goals. (Educator material (not peer reviewed); Therapeutic Goods Administration, SANDOSTATIN LAR octreotide modified-release injection vial plus diluent (ARTG 227963), public ARTG record checked 2026-10-28, 2026-10-28)
- The Australian product information contraindicates hypersensitivity to octreotide or formulation components. It warns about gallbladder and biliary effects, altered glucose regulation, gastrointestinal effects, bradycardia, injection-site reactions, and rare pancreatitis; risk and monitoring depend on the indication and treatment duration. (Manufacturer information; Therapeutic Goods Administration, AusPAR: Octreotide; Australian Sandostatin LAR Product Information approved with AusPAR, final 2012-02-14, 2012-02-14)
- The depot and immediate-release formulations are not route-interchangeable: the cited LAR product information requires intramuscular administration and says not to administer the depot intravenously. (Manufacturer information; Therapeutic Goods Administration, AusPAR: Octreotide; Australian Sandostatin LAR Product Information approved with AusPAR, final 2012-02-14, 2012-02-14)
- The label details here use the static TGA AusPAR product-information attachment finalised 2012-02-14; the ARTG record links a separate Product Information document, so verify the current PI before approving this draft. (Educator material (not peer reviewed); Therapeutic Goods Administration, SANDOSTATIN LAR octreotide modified-release injection vial plus diluent (ARTG 227963), public ARTG record checked 2026-10-28, 2026-10-28)
Sources
- Therapeutic Goods Administration, AusPAR: Octreotide; Australian Sandostatin LAR Product Information approved with AusPAR, final 2012-02-14 (2012-02-14)
- Therapeutic Goods Administration, SANDOSTATIN LAR octreotide modified-release injection vial plus diluent (ARTG 227963), public ARTG record checked 2026-10-28 (2026-10-28)
Dosing, stacking and protocol details are not published here.